Ep209: Mathai Mammen on Developing Drugs Against Undruggable Targets

The Long Run with Luke Timmerman by The Long Run with Luke Timmerman

Sep 9, 202601:36:12Science & Medicine

Mathai Mammen, CEO of Cambridge, Mass.-based Parabilis Medicine, on developing alpha helical peptide molecules against hard targets of disease.

Related Episodes

Continue listening to more episodes from The Long Run with Luke Timmerman.

Aug 25, 2026 - 01:07:17

Gary Nabel, CEO of Weston, Mass.-based ModeX Therapeutics, on developing a vaccine for Epstein-Barr Virus...

Aug 11, 2026 - 01:17:31

Jason Coloma, CEO of South San Francisco-based Maze Therapeutics, on developing small molecule drugs base...

Jul 28, 2026 - 01:07:17

Lyn Baranowski, CEO of Boston-based Avalyn Pharma, on developing inhalable medicines for severe lung dise...

Jul 14, 2026 - 01:08:18

Heather Turner, CEO of New York-based LB Pharma, on developing a new schizophrenia drug designed to bette...

Jun 30, 2026 - 01:07:27

Troy Wilson, CEO of San Diego-based Kura Oncology, on his career in biotech and developing targeted cance...

Jun 16, 2026 - 01:11:43

Sri Kosuri, co-founder and CEO of Emeryville, Calif.-based Octant Bio, on small molecules designed to cor...

Jun 2, 2026 - 01:08:12

Becky Pferdehirt, CEO of Emeryville, CA-based Radial, the life sciences unit of Astera Institute, on reim...

May 19, 2026 - 01:08:40

Jeremy Levin, executive chair of Ovid Therapeutics, discusses his new book "Biotech in the Balance: Savin...